The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Pfizer
Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16).
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Bong-Seog Kim
No Relationships to Disclose
 
Ho Yeong Lim
No Relationships to Disclose
 
Hee Jun Kim
No Relationships to Disclose
 
Inkeun Park
No Relationships to Disclose
 
Yoon Ji Choi
No Relationships to Disclose
 
Kyong Hwa Park
No Relationships to Disclose
 
Kyung Hee Lee
No Relationships to Disclose
 
Shinkyo Yoon
No Relationships to Disclose
 
Bumsik Hong
No Relationships to Disclose
 
Jun Hyuck Hong
No Relationships to Disclose
 
Hanjong Ahn
No Relationships to Disclose